Discover
APRE
Aprea Therapeutics, Inc.
0.75
1 x 0.79
2 x 0.86
bid
ask
-
0.06
7.13%
2 @ 07:00 AM
0.77 +0.02 (2.70%)
| Ytd | -12.65% | |
| 1y | -54.84% |
0.71
day range
0.81
0.55
52 week range
2.22
| Open | 0.80 | Prev Close | 0.80 | Low | 0.71 | High | 0.81 | Mkt Cap | 9.23M |
| Vol | 165.46K | Avg Vol | 209.35K | EPS | -1.49 | P/E | N/A | Forward P/E | -3.08 |
| Beta | 1.74 | Short Ratio | 0.55 | Inst. Own | 43.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.83 | 200-d Avg | 0.98 | 1yr Est | 15.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.75 | -0.64 | 0.11 | 14.67% |
| 2024-08-12 | 2024-06 | -0.64 | -0.58 | 0.06 | 9.38% |
| 2024-08-12 | 2024-06 | -0.64 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.78 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.78 | -0.67 | 0.11 | 14.10% |
| 2024-03-26 | 2023-12 | -0.56 | -0.92 | -0.36 | -64.29% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-13 | Wedbush | Upgrade | Outperform | Outperform |
| 2024-08-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-17 | DUEY MARC | Director | 234.25K | Sale |
| 2024-10-22 | GILAD OREN PH.D. | Chief Executive Officer | 335.20K | Purchase |
| 2024-06-19 | GRISSINGER MICHAEL J. | Director | 1.84K | Stock Award(Grant) |
| 2024-10-10 | HAMILL JOHN P | Chief Financial Officer | 19.37K | Purchase |
| 2024-06-19 | HENNEMAN JOHN BELL III | Director | 9.18K | Stock Award(Grant) |
| 2024-04-30 | MIRZA NADEEM Q. | Officer | 6.73K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | AIGH Capital Management LLC | 539.30K | 1.69M | 9.92% |
| 2024-09-29 | Sio Capital Management, LLC | 276.60K | 868.53K | 5.09% |
| 2024-09-29 | Sphera Funds Management Ltd. | 270.00K | 847.80K | 4.97% |
| 2024-09-29 | Nantahala Capital Management, LLC | 205.76K | 646.09K | 3.79% |
| 2024-09-29 | Vanguard Group Inc | 173.84K | 545.86K | 3.20% |
| 2024-09-29 | Stonepine Capital Management, LLC | 137.17K | 430.73K | 2.52% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 145.28K | 456.18K | 2.67% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 28.56K | 89.68K | 0.53% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 25.28K | 79.36K | 0.47% |
| 2024-10-30 | Fidelity Total Market Index Fund | 7.20K | 22.60K | 0.13% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 5.96K | 18.72K | 0.11% |
| 2024-07-30 | Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 5.08K | 15.96K | 0.09% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2023-02-13 |
| 1 : 1000 | 2018-12-27 |